Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal Pemetrexed for Leptomeningeal Metastasis
NCT05289908Phase 2Completed
- Sponsor
- The First Hospital of Jilin University
- Start
- Feb 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pemetrexed in leptomeningeal metastases (LM) (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoints: Maximal Tolerated Dose at 2 months and Incidence of treatment-related adverse events at 2 months. Started Feb 2022; status: completed.
02
Drugs
pemetrexed
03
Conditions
leptomeningeal metastases (LM)
Beyond the preview
Go deeper on NCT05289908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289908.